Phosphagenics in for Indian royalties from TPM gels

Phosphagenics (ASX:POH) has announced the launch of two anti-inflammatory products in India that use its targeted penetration matrix (TPM) drug-delivery technology.

Multinational pharmaceutical company Novartis has launched Voveran TPM Gel, a topical diclofenac gel formulated with the TPM system.

Phosphagenics’ Indian marketing partner, Themis Medicare, is also gearing up to launch its own diclofenac product incorporating TPM under the product name Instanac TPM Gel.

Themis Medicare took out a licence to use Phosphagenics’ TPM technology in a branded diclofenac product in late 2011. Last year, the company entered an agreement with Novartis to manufacture and supply the Voveran TPM Gel.

Under the terms of these deals, Phosphagenics is entitled to undisclosed royalties on sales of both branded products.

Voveran TPM gel will be marketed for the treatment of pain and inflammation of the muscles and joints caused by osteoarthritis, soft tissue rheumatism and injuries such as sprains and strains. The product packaging will highlight the use of the TPM delivery system.

Phosphagenics (ASX:POH) shares were trading unchanged at $0.13 as of around 2 pm on Tuesday.